Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Both Ipsen News

Both Ipsen News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Both Ipsen. Real-time updates on events, politics, business and more.

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Ate

December 9, 2022
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus docetaxel in p...
United States Susan Hubbard Lindsay Treadway Daiichi Sankyo Company Health Professional Version Exchange Commission
Source: pharmiweb.com

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atez

December 9, 2022
The trial did not meet its primary endpoint of overall survival (OS)The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single agentThe clinical trial results will be presented at a future medical meetingPARIS--(BUSINESS WIRE)--Regulatory News...
France General United States United Kingdom Howard Mayer Ioana Piscociu Ipsen Euronext
Source: pharmiweb.com

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

December 8, 2022
The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for
France General United States United Kingdom Howard Mayer Ioana Piscociu Ipsen Euronext
Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science